Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer

Open access
Date
2018-04-23Type
- Journal Article
Abstract
Abstract: Single-nucleotide polymorphisms (SNPs) can severely impact individual drug response and health outcomes in cancer patients. Genetic tests to screen for marker SNPs are available to adjust the drug dose of oncologicals to the patient’s needs. However, it is unclear whether the positive effects outbalance the increased costs or even lead to an overall cost reduction. This very pragmatic analysis used three frequently used oncologicals for the treatment of breast cancer to evaluate whether preemptive pharmacogenetic testing may have a cost-reducing impact on health care spending in the Swiss health care system. Our results indicate that oncopharmacogenetics might help to reduce health care costs (ie, by avoiding adverse drug effects) and to increase efficiency of drugs in oncologic patients. Show more
Permanent link
https://doi.org/10.3929/ethz-b-000314666Publication status
publishedExternal links
Journal / series
PHARMACOGENOMICS & PERSONALIZED MEDICINEVolume
Pages / Article No.
Publisher
BenthamSubject
pharmacogenetics; oncology; budget impact model; Switzerland; health insuranceMore
Show all metadata